Pilot study of oral eniluracil/5-FU in the palliation of hormone-refractory prostate cancer

Prostate Journal

Volumn 3, Issue 1, 2001, Pages 30-35

  Rosenthal, Mark A ^a   Thomas, David ^b   Davis, Ian ^c   Toner, Guy ^b   Noordin, Naeem ^d   Zalcberg, John ^b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c AUSTIN HEALTH   (Australia)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 ETHYNYLURACIL; ANTINEOPLASTIC AGENT; FLUOROURACIL; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANALGESIA; ANEMIA; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG ACTIVITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG TOLERABILITY; HUMAN; LETHARGY; LIVER DYSFUNCTION; MALE; PAIN ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE;

EID: 0034844319     PISSN: 10955100     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1411.2001.003001030.x     Document Type: Article

References (17)

1. Cancer statistics
2. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative endpoints
3. Chemotherapy of advanced prostatic cancer
4. Management of hormone refractory prostate cancer: Current standards and future prospects
5. Cytotoxic chemotherapy for advanced hormone resistant prostate cancer
6. Continous systemic 5-FU infusion in refractory prostate cancer
7. A phase II study of continuous 5-FU in advanced hormone refractory prostate cancer: An Illinois Cancer Center Study
8. 5-ethynyluracil (776C85): Inactivation of dihydropyrimidine dehydrogenase in vivo
9. Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors
10. 5-Ethynyuracil (776C85): Modulation of 5-FU efficacy and therapeutic index in rats bearing advanced colorectal carcinoma
11. Patient preferences for oral versus intravenous chemotherapy
12. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument
13. Reporting the results of cancer treatment
14. Management of metastatic prostate cancer
15. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network-Phase III trial
16. Hydrocortisone with or without Mitoxantrone in men with hormone refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study
17. Apples and oranges: Building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials